Clinical trials: Helicobacter Infections
HELICOBACTER PYLORI INFECTIONS, Metabolic Syndrome
Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.
The Role of Gut Microbiota in the Mechanism of Helicobacter pylori Eradication-Induced Amelioration of Metabolic Syndrome-Related Parameters Study Sponsor: Nanjing First Hospital Principal Investigator: Dr.
- Trial name
- NCT07306988
- Testing
- Vonoprazan-Amoxicillin Dual Therapy, Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae, Vonoprazan-Amoxicillin with Berberine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
HELICOBACTER PYLORI INFECTIONS
Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
This study aims to provide an updated analysis of the resistance patterns of H. pylori in the Nanjing region, with a focus on characterizing the current status of phenotypic and genotypic resistance to these six antimicrobial…
- Trial name
- NCT07455448
- Testing
- Antimicrobial susceptibility testing
- Where
- China
- Volunteers
- 7,227 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
HELICOBACTER PYLORI INFECTIONS
Registry for the Management of Helicobacter Pylori Infection in Shandong Province
Helicobacter pylori infection is a common global gastrointestinal infectious disease, affecting approximately 43.1% of the world's population. Eradicating H.
- Trial name
- Hp-SHAREReg (NCT07335406)
- Testing
- Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstance, not involve any intervention procedure.
- Where
- 2 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Yueyue Li
Helicobacter Pylori Infection
Optimization of Minocycline for Helicobacter Pylori Rescue Treatment
The efficacy of bismuth-containing quadruple therapy with minocycline and metronidazole was not inferior to classical bismuth quadruple therapy for refractory H.
- Trial name
- NCT06561711
- Testing
- Vonoprazan, Bismuth Potassium Citrate, Tetracycline,Metronidazole
- Where
- 4 sites in China
- Volunteers
- 480 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Gut Microbiota, Metabolic Profiles
Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity
Patients with concurrent Helicobacter pylori infection and small intestinal bacterial overgrowth (SIBO) represent a clinically challenging subgroup, often experiencing refractory gastrointestinal symptoms and diminished treatment…
- Conditions
- Gut Microbiota, Metabolic Profiles, Helicobacter Pylori Infection, Small Intestinal Bacterial Overgrowth
- Trial name
- NCT07122284
- Testing
- 13C-Urea Breath Test, Hydrogen-Methane Breath Test
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
HELICOBACTER PYLORI INFECTIONS, Intestinal Metaplasia
Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy
The goal of this observational study is to learn how common Helicobacter pylori (H. pylori) infection is in adults without stomach or upper gastrointestinal symptoms who are having a preventive screening colonoscopy.
- Conditions
- HELICOBACTER PYLORI INFECTIONS, Intestinal Metaplasia, Barett's Esophagus
- Trial name
- G-SCOGE (NCT07346521)
- Where
- Austria
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sigmund Freud PrivatUniversitat
Peptic Ulcer Disease, HELICOBACTER PYLORI INFECTIONS
Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound
This observational study aims to evaluate whether combining a simple blood test (H. pylori serology) with a non-invasive abdominal ultrasound can accurately predict severe complications in patients with peptic ulcer disease…
- Conditions
- Peptic Ulcer Disease, HELICOBACTER PYLORI INFECTIONS, Helicobacter Pylori Infection, Peptic Ulcer
- Trial name
- NCT07458490
- Volunteers
- 230 people
- Sponsor
- Assiut University
Helicobacter Pylori Infection, Tegoprazan
Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study
To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and…
- Conditions
- Helicobacter Pylori Infection, Tegoprazan, Furazolidone
- Trial name
- NCT06340334
- Testing
- Tegoprazan-amoxicillin dual therapy
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection
Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
It is planned to select Hp infection patients in a number of tertiary hospitals in Jiangsu and randomly divide them into three groups: group A is the classic group, receiving Vonoprazan 20mg, bid + amoxicillin 1.0g, bid +…
- Trial name
- NCT06412588
- Testing
- Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days, Vonoprazan+Amoxicillin, Vonoprazan+doxycycline
- Where
- China
- Volunteers
- 579 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection, Helicobacter Pylori
H. Pylori Eradication With Argon Plasma During Endoscopy
The objective of the study is to investigate the efficacy and safety of an argon plasma-based therapy - HEAPE - in treating H. pylori infections during endoscopic procedures.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Pylori, Helicobacter Pylori Gastrointestinal Tract Infection, H. Pylori Infection
- Trial name
- HEAPE (NCT06529159)
- Testing
- HEAPE, Pre-HEAPE
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Christopher C. Thompson, MD, MSc
Gastric (Stomach) Cancer, Helicobacter Infection
An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori
This study is intended to be a prospective observational cohort study. The incidence of gastric cancer and progression of gastric precancerous lesions will be compared between groups through prospective follow-up of a population…
- Trial name
- NCT06896370
- Testing
- observational study
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fudan University
Helicobacter Pylori Infection
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication
Vonoprazan and high-dose amoxicillin dual therapy was used as a control group to evaluate the clinical efficiency and safety of Banxiaxiexin decoction combined with vonoprazan and high-dose amoxicillin dual therapy in the…
- Trial name
- NCT06340724
- Testing
- Vonoprazan, Amoxicillin, Banxiaxiexin decoction
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection
Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy
Background：Helicobacter pylori infection is a well-established risk factor for peptic ulcer disease and gastric cancer. It's now a consensus of experts that H.pylori infection should be treated once it is recognized.
- Trial name
- NCT06156085
- Testing
- Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole
- Where
- Taiwan
- Volunteers
- 337 people
- Sponsor
- Fu Jen Catholic University Hospital
Helicobacter Pylori Infection, Helicobacter Pylori Eradication Antibiotic
The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
This clinical controlled study enrolled 73 H. pylori（Helicobacter Pylori ）-infected female participants, stratified into reproductive-age and menopausal cohorts, alongside 10 non-infected controls.
- Trial name
- NCT07408271
- Testing
- rabeprazole-based triple therapy plus bismuth H. pylori eradication therapy
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HELICOBACTER PYLORI INFECTIONS
Fecal Molecular Susceptibility-guided Hp First-line Therapy
The goal of this clinical trial is to evaluate the eradication efficacy and health economic benefits of individualized regimens guided by fecal molecular susceptibility testing with 7-day and 14-day courses in the first-line…
- Trial name
- NCT07405684
- Testing
- 7-day fecal molecular susceptibility-guided therapy, 14-day fecal molecular susceptibility-guided therapy
- Where
- 4 sites in China
- Volunteers
- 544 people
- Sponsor
- Shanghai Zhongshan Hospital
Helicobacter Pylori Infection
Fecal Molecular Susceptibility-guided Hp Rescue Therapy
The goal of this clinical trial is to evaluate the eradication efficacy and health economic benefits of individualized regimens guided by fecal molecular susceptibility testing with 7-day and 14-day courses in the rescue…
- Trial name
- NCT07405697
- Testing
- 7-day fecal molecular susceptibility-guided therapy, 14-day fecal molecular susceptibility-guided therapy
- Where
- 4 sites in China
- Volunteers
- 290 people
- Sponsor
- Shanghai Zhongshan Hospital
HELICOBACTER PYLORI INFECTIONS
Real-World Study of Helicobacter Pylori Eradication Success and Its Determinants
This study aims to evaluate the real-world effectiveness of different treatment regimens used to eradicate Helicobacter pylori (H. pylori) infection in routine clinical practice. H.
- Trial name
- NCT07374822
- Testing
- No Study-Assigned Intervention
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Run-hua Li
Helicobacter Pylori Infection
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy
(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H.
- Trial name
- NCT07358130
- Testing
- vonoprazan, tripotassium dicitrate bismuthate, amoxicilline, rabeprazole, tripotassium dicitrate bismuthate, tetracycline, metronidazole
- Where
- Taiwan
- Volunteers
- 552 people
- Sponsor
- Kaohsiung Medical University
Helicobacter Pylori Infection
Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)
Standard eradication therapies using proton pump inhibitors (PPIs) require double doses to achieve sufficient acid suppression, yet failure rates remain high due to antibiotic resistance.
- Trial name
- TATH-1 (NCT05647278)
- Testing
- Tegoprazan 50 mg, tablets, orally, qd, Esomeprazole 20mg BID, Tegoprazan 50 mg, tablets, orally, bid
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Zhang Xiaofeng,MD
Gastric Cancer Screening, Prevention and Control
Helicobacter Pylori Infection and Gastric Diseases in Lao PDR: First Community-Wide Population-Based Study
This study aims to determine the regional prevalence of Helicobacter pylori infection, bacterial strain differences, and the prevalence of gastric cancer in two provinces of Laos, a multi-ethnic country where these factors may…
- Conditions
- Gastric Cancer Screening, Prevention and Control, Helicobacter Eradication, Helicobacter Infections
- Trial name
- NCT07340593
- Where
- Laos
- Volunteers
- 1,251 people, healthy volunteers welcome
- Sponsor
- Zero Helicobacter IGAN Network